Search Follow us

Immutep (IMM)

Business description

Immutep has a pipeline of four LAG-3 related product candidates: eftilagimod alpha (IMP321) for cancer chemo-immunotherapy and immunotherapy-immunotherapy combinations, two partnered products IMP731 (GSK) and IMP701 (Novartis), as well as IMP761 for autoimmune diseases.

Stock data

Market cap.A$120m
Last closeA$0.04
High / Low (52 weeks)A$84.5 / A$35.5
Stock market listingAU
Forecast net cash (A$m)10
Forecast gearing ratio (%)N/A
TeamHealthcare
SectorPharmaceutical & healthcare

Price performance

%1m3m12m
Actual(13.3)14.762.5
Relative *(11.1)25.970.2

* % Relative to local index

Other companies in sector Show

4SC aap Implantate
Aastrom Biosciences AB Science
Abcam Abivax SA
Ablynx Abzena
Acacia Pharma Acarix
Acerus Pharmaceuticals Achillion Pharmaceuticals
Acorda Therapeutics Actinium Pharmaceuticals
Active Biotech Acucela
Addex Therapeutics Adherium
ADL Bionatur Solutions Adocia
Advanced Medical Solutions Aegerion Pharmaceuticals
Aeterna Zentaris AFT Pharmaceuticals
Agennix Akari Therapeutics
Alchemia Alexza Pharmaceuticals
Algeta Alimera Sciences
ALK Abello Alkermes
Allergy Therapeutics Alliance Pharma
Allium Medical Solutions Alnylam Pharmaceuticals
Amarantus BioScience Amarin
Amplifon AmpliPhi Biosciences
Angle Animalcare Group
Anteo Diagnostics Anthera Pharmaceuticals
Antibe Therapeutics Aratana Therapeutics
Ardea Biosciences Ardelyx
Arena Pharmaceuticals arGEN-X
Argos Therapeutics Ariad Pharmaceuticals
Arix Bioscience Ark Therapeutics Group
ArQule Array BioPharma
Arrowhead Research Corporation Ascendis Pharma
ASIT Biotech ASLAN Pharmaceuticals
Astex Pharmaceuticals Athersys
Atossa Genetics Auris Medical Holding
Avacta Group Avalanche Biotechnologies
AVEO Pharmaceuticals Avita Medical
Avivagen Balda
Basilea Pharmaceutica Bavarian Nordic
Bellus Health Benitec Biopharma
BioCryst Pharmaceuticals BioInvent
BioLargo BioLight Life Sciences
BioLineRx BiondVax Pharmaceuticals
Bionomics Bionor Pharma
BioPorto Diagnostics Biota Holdings
Biotie Therapies Corp Biotron
Bluebird Bio Bone Therapeutics
Bonesupport BrainStorm Cell Therapeutics
Brighter BTG
C4X Discovery Holdings Caladrius Biosciences
Can-Fite BioPharma CannTrust Holdings
Cantargia Capstone Therapeutics
Carmat CASI Pharmaceuticals
Cell Therapy Celldex Therapeutics
Cellectis Cellular Biomedicine Group
Celyad Cerulean Pharma
Circadian Technologies Circassia Pharmaceuticals
Clal Biotechnology Industries Clavis Pharma
Cleveland BioLabs Clinigen Group
Clinuvel CO.DON
CollPlant Holdings Consort Medical
Corium International Crescendo
Crossject CSL
Curetis NV Curis
Cytori Therapeutics Cytos Biotechnology
CytRx Corporation DBV Technologies
Dechra Pharmaceuticals Deinove
Delcath Systems Deltex Medical
Derma Sciences Destiny Pharma
DiaSorin Diaxonhit
e-Therapeutics Egalet Corporation
EKF Diagnostics Elbit Medical Technologies
Ellex Medical Lasers Emergent BioSolutions
Endocyte Epigenomics
Ergomed Erytech Pharma
Esperion Therapeutics Evotec
Exact Sciences Exelixis
Expedeon EyeGate Pharmaceuticals
Factor Therapeutics Formycon
Forward Pharma Fresenius SE & Co. KGaA
Futura Medical Galapagos
Galmed Pharmaceuticals Genedrive
Genfit Genkyotex
Genmab GeoVax
GI Dynamics Gilead Sciences
GNI Group Ltd GW Pharmaceuticals
Halozyme Therapeutics Heat Biologics Inc.
Heidelberg Pharma Herantis Pharma
Horizon Discovery Hutchison China MediTech
Hybrigenics iCo Therapeutics
Idenix Immune Pharmaceuticals
Immunicum Immunodiagnostic Systems Holdings
Immunovia ImmuPharma
Imprimis Pharmaceuticals Imugene
Incyte Corporation Infinity Pharmaceuticals
InflaRx InMed Pharmaceuticals
Innate Pharma Insmed
Intec Pharma International Stem Cell
Invion Ion Beam Applications
Ipsogen Iridex
Ironwood Pharmaceuticals Islet Sciences
Ixico Japan Tobacco
KaloBios Pharmaceuticals Kane Biotech
Karolinska Development Kazia Therapeutics
Keryx Biopharmaceuticals Kiadis Pharma
Laboratorios Farmacéuticos ROVI LCA-Vision
LeMaitre Vascular Lifeline Scientific
LifeWatch Ligand Pharmaceuticals
Lipocine Lombard Medical Technologies
MagForce Mast Therapeutics
Medcom Tech Medicago
MediciNova Medicure
Medigene Medivir
Merrimack Pharmaceuticals Merrion Pharmaceuticals
Mesoblast MethylGene
MGC Pharmaceuticals Midatech Pharma
MISSION Therapeutics Molecular Partners
MolMed Mologen
Momenta Pharmaceuticals MorphoSys
Nanobiotix Nanosonics
Navidea Biopharmaceuticals Nektar Therapeutics
NeoStem Neovacs
NetScientific NeuroVive Pharmaceutical
Newron Pharmaceuticals Nexstim
NicOx NMC Health
NorDiag Nordion
NovaBay Pharmaceuticals Novacyt
NPS Pharmaceuticals Nuevolution
Ocata Therapeutics Omega Diagnostics Group
Omeros Corporation OncoGenex Pharmaceuticals
Oncology Venture Oncolytics Biotech Inc
OncoMed Pharmaceuticals Onconova Therapeutics
Oncothyreon Onxeo
Onyx Pharmaceuticals Opexa Therapeutics
OPMEDIC Group Optos
Orexigen Therapeutics Orexo
Orgenesis Oryzon Genomics
OSE Immunotherapeutics Ossur
OvaScience OWL
Oxford BioMedica Oxford Immunotec
Pacific Edge Paion
Paladin Labs Patheon
PBKM PDL BioPharma
Pharmacyclics PharmaMar
Pharmaxis Pharming Group
Photocure Phylogica
Pixium Vision Pluristem Therapeutics
Prescient Therapeutics Probiodrug
ProMetic Life Sciences Prosensa
Proteome Sciences PsiOxus
QRxPharma Quantum Genomics
Quantum Pharmaceuticals Race Oncology
RedHill Biopharma Regeneus
Relmada Therapeutics ReNeuron Group
Resverlogix REVA Medical
Rovi RXi Pharmaceuticals
Sangamo BioSciences Sarepta Therapeutics
Sartorius Scancell
Selvita Shire
Sierra Oncology Silence Therapeutics
Simavita Sinclair Pharma
Sirtex Medical Skyepharma
Smith & Nephew Sobi
Sosei Group Corporation Source Bioscience
SQI Diagnostics Stallergenes
StemCells Stentys
Stratec Biomedical Sucampo Pharmaceuticals
Sunesis Pharmaceuticals Surgical Innovations
Sygnis SymBio Pharmaceuticals
Synairgen Synergy Health
Synta Pharmaceuticals T‐cell cancer therapies
Targovax TearLab Corp
Tekmira Telix Pharmaceuticals
TESARO Theraclion
Therapix Biosciences Threshold Pharmaceuticals
ThromboGenics TiGenix
Tissue Regenix Tissue Therapies
Titan Pharmaceuticals Tonix Pharmaceuticals
Topotarget Touchstone Innovations
Transgene Trillium Therapeutics
True Leaf TruScreen
TxCell UCB
UDG Healthcare uniQure NV
Universal Biosensors VBI Vaccines
Vectura Verastem
Verisante Technology Vernalis
Verona Pharma Vertex Pharmaceuticals
Viralytics ViroPharma
Vivalis Vivus
VolitionRx WaferGen Biosystems
Xbrane Biopharma Xencor
Zafgen Zealand Pharma
Ziopharm Oncology

Company news

Prima BioMed Changes Its Name to Immutep Ltd

Mon, 20 Nov 2017 06:56:15 GMT

BRIEF-Immutep Ltd Enters Into Clinical Trial Collaboration With Merck & Co

Mon, 12 Mar 2018 01:18:45 GMT

Immutep to Present Interim Results from TACTI-mel Clinical Trial in Global Webcast

Thu, 17 May 2018 12:00:00 GMT

Immutep Limited Announces Milestone Payment From Chinese Partner EOC Pharma

Thu, 01 Feb 2018 03:00:00 GMT

Prima BioMed Becomes Immutep

Tue, 28 Nov 2017 00:11:15 GMT

Y/E Jun Revenue (A$m) EBITDA (A$m) PBT (A$m) EPS (c) P/E (x) P/CF (x)
2017A 4.1 (7.8) (8.4) (0.4) N/A N/A
2018A 6.9 (11.4) (10.9) (0.5) N/A N/A
2019E 10.9 (7.6) (6.9) (0.2) N/A N/A
2020E 2.8 (15.3) (14.9) (0.5) N/A N/A

Last updated on 22/11/2018

Investment summary

Immutep has three promising candidates in clinical trials and one preclinical asset, all based on Lymphocyte activation gene-3, LAG-3 (one partnered with GSK and a second partnered with Novartis). Lead in-house LAG-3 product, eftilagimod alpha (efti), is being developed in metastatic breast cancer combined with chemo (155 of 226 patients recruited in randomised Phase IIb, initial PFS data expected H219) and in melanoma in combination with Keytruda (33% response rate in three dose-finding cohorts, 61% response rate from start of Keytruda monotherapy screening). Novartis and GSK are progressing clinical trials of partnered LAG-3 programmes: GSK has announced ulcerative colitis as lead indication; Novartis has commenced three Phase II studies with LAG525 this year. Immutep will collaborate with Merck & Co (MSD) in a study of efti plus Keytruda in lung and head and neck cancers in Q418. A trial of efti plus Bavencio in advanced solid tumours in collaboration with Merck KGaA/Pfizer is also planned.

Last updated on 29/11/2018

Industry outlook

Immunotherapies are among the most promising class of products for cancer and autoimmune diseases. The LAG-3 products are potentially first-in-class, each with distinct mechanisms and applications.

Last updated on 29/11/2018

Key management

Marc Voigt , CEO
Jay Campbell, Senior Director, Business Development

Company address

Level 12, 95 Pitt Street
Sydney
NSW
2000
Australia
View website